HealthCor Management L.P. increased its position in shares of Zoetis Inc (NYSE:ZTS) by 61.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 645,100 shares of the company’s stock after purchasing an additional 246,460 shares during the quarter. Zoetis accounts for 1.5% of HealthCor Management L.P.’s investment portfolio, making the stock its 26th biggest holding. HealthCor Management L.P. owned approximately 0.13% of Zoetis worth $46,473,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Quantbot Technologies LP acquired a new position in Zoetis during the third quarter worth $3,972,000. Daiwa SB Investments Ltd. raised its holdings in Zoetis by 92.0% during the fourth quarter. Daiwa SB Investments Ltd. now owns 18,152 shares of the company’s stock worth $1,308,000 after purchasing an additional 8,696 shares during the last quarter. BLB&B Advisors LLC raised its holdings in Zoetis by 5.2% during the fourth quarter. BLB&B Advisors LLC now owns 50,460 shares of the company’s stock worth $3,635,000 after purchasing an additional 2,478 shares during the last quarter. King Luther Capital Management Corp raised its holdings in Zoetis by 3.7% during the third quarter. King Luther Capital Management Corp now owns 1,264,164 shares of the company’s stock worth $80,603,000 after purchasing an additional 44,697 shares during the last quarter. Finally, California Public Employees Retirement System raised its holdings in Zoetis by 4.5% during the third quarter. California Public Employees Retirement System now owns 1,295,752 shares of the company’s stock worth $82,617,000 after purchasing an additional 55,852 shares during the last quarter. 92.45% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on ZTS shares. Cowen set a $80.00 price objective on Zoetis and gave the stock a “buy” rating in a report on Friday, November 17th. UBS Group reaffirmed a “neutral” rating on shares of Zoetis in a report on Friday, November 24th. Morgan Stanley raised Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective for the company in a report on Wednesday, November 29th. Cantor Fitzgerald set a $80.00 price objective on Zoetis and gave the stock a “buy” rating in a report on Tuesday, December 12th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $85.00 price objective (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus price target of $80.28.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.69 EPS for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.03. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.47 earnings per share. sell-side analysts forecast that Zoetis Inc will post 3.04 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be given a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio is currently 28.57%.
In other news, EVP Roxanne Lagano sold 35,663 shares of Zoetis stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the sale, the executive vice president now owns 49,919 shares of the company’s stock, valued at $4,044,437.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Roman Trawicki sold 23,885 shares of Zoetis stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $82.00, for a total value of $1,958,570.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 97,001 shares of company stock valued at $7,882,428. Company insiders own 0.31% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.